4.0 Review

Report of the International Society for Clinical Densitometry 2007 adult Position Development Conference and official positions

期刊

SOUTHERN MEDICAL JOURNAL
卷 101, 期 7, 页码 735-739

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SMJ.0b013e31817a8b02

关键词

BMD; DXA; guidelines; ISCD; osteoporosis

向作者/读者索取更多资源

The International Society for Clinical Densitometry (ISCD) periodically holds Position Development Conferences (PDCs) for the purpose of establishing standards and guidelines for the assessment of skeletal health-the nomenclature, indications, acquisition, analysis, quality control, interpretation, and reporting of bone density tests. Topics are selected for consideration according to criteria that include clinical relevancy, uncertainty in the application of medical evidence to clinical practice, and the likelihood of the expert panel achieving agreement. The most recent Adult PDC was held July 20 to 22, 2007, in Lansdowne, Virginia. Topics included technical and clinical issues relevant to dual-energy x-ray absorptiometry (DXA), vertebral fracture assessment, and bone densitometry technologies other than central DXA. This report describes the methodology and presents the results of this PDC. The first ISCD Pediatric PDC was held June 20 to 21, 2007 in Montreal, Quebec, Canada, and is reported separately.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Endocrinology & Metabolism

Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services

W. F. Lems, J. Paccou, J. Zhang, N. R. Fuggle, M. Chandran, N. C. Harvey, C. Cooper, K. Javaid, S. Ferrari, K. E. Akesson

Summary: Vertebral fractures are independent risk factors for future fractures, and VFA in FLS plays a crucial role in detecting vertebral fractures for secondary fracture prevention. Additional information from VFA may influence treatment initiation and type by providing baseline vertebral fracture data.

OSTEOPOROSIS INTERNATIONAL (2021)

Review Endocrinology & Metabolism

Operationalizing Treat-to-Target for Osteoporosis

E. Michael Lewiecki

Summary: Treat-to-target for osteoporosis focuses on individualizing patient treatment decisions to achieve an acceptable level of fracture risk, with bone mineral density being commonly used as a surrogate measure for assessing reduction of fracture risk. Studies have shown a strong correlation between increases in BMD with treatment and reductions in fracture risk. More research is needed to fully validate the use of TTT for osteoporosis in clinical practice.

ENDOCRINOLOGY AND METABOLISM (2021)

Biographical-Item Endocrinology & Metabolism

In Memoriam: Elliott N. Schwartz, MD

E. Michael Lewiecki, John P. Bilezikian, Neil Binkley, Robin K. Dore, Paul D. Miller, Kelly Krohn, S. Bobo Tanner

JOURNAL OF CLINICAL DENSITOMETRY (2022)

Article Endocrinology & Metabolism

Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases

E. Michael Lewiecki, Paul A. Anderson, John P. Bilezikian, Neil Binkley, Angela M. Cheung, Erik A. Imel, Diane Krueger, Michael R. McClung, Paul D. Miller, Micol S. Rothman

Summary: The 2021 Virtual Santa Fe Bone Symposium was a conference aimed at improving the care of patients with skeletal disorders. It attracted over 300 attendees from the USA and other countries. The conference covered various aspects of skeletal diseases and provided interactive sessions such as lectures, case presentations, and panel discussions to share the latest research findings and care strategies.

JOURNAL OF CLINICAL DENSITOMETRY (2022)

Review Endocrinology & Metabolism

Evaluating Patients for Secondary Causes of Osteoporosis

E. Michael Lewiecki

Summary: The evaluation of patients with osteoporosis is crucial for correct diagnosis, identifying correctable factors, and assisting in personalized management decisions.

CURRENT OSTEOPOROSIS REPORTS (2022)

Article Endocrinology & Metabolism

A retrospective observational study of osteoporosis management after a fragility fracture in primary care

Alan Bell, David L. Kendler, Aliya A. Khan, Marla C. M. Shapiro, Anne Morisset, Jean-Pierre Leung, Maureen Reiner, Stephen M. Colgan, Lubomira Slatkovska, Millicent Packalen

Summary: In many countries, primary care physicians are responsible for managing osteoporosis; however, the management after a fragility fracture has not been extensively studied. This study examines the gaps in osteoporosis care in a real-world patient cohort, providing valuable insights to overcome obstacles to effective management of patients after fragility fractures.

ARCHIVES OF OSTEOPOROSIS (2022)

Review Endocrinology & Metabolism

The current role of telehealth in the management of patients with osteoporosis

E. Michael Lewiecki, Matthew F. Bouchonville

Summary: This article reviews the application of telehealth and teleeducation in the care of osteoporosis and introduces related programs and models. Telemedicine has been widely used during the COVID-19 pandemic and provides opportunities for reducing the burden of osteoporotic fractures globally.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2022)

Article Endocrinology & Metabolism

The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial

Edward Czerwinski, Jose Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G. Saag, Neil Binkley, E. Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll, Yinzhong Chen, Leny Pearman, Y. Heather Li, Bruce Mitlak

Summary: The study shows that Abaloparatide significantly increases bone mineral density in men with osteoporosis and has a safety profile consistent with previous studies. These results suggest that Abaloparatide can be considered as an effective anabolic treatment option for male patients with osteoporosis.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

Review Endocrinology & Metabolism

Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases

E. Michael Lewiecki, John P. Bilezikian, Neil Binkley, Mary L. Bouxsein, Susan V. Bukata, David W. Dempster, Matthew T. Drake, Michael R. McClung, Paul D. Miller, Elisabeth Rosenthal, Laura L. Tosi

Summary: The 22nd Annual Santa Fe Bone Symposium was held in a hybrid format with over 400 attendees. The symposium covered various topics related to skeletal health and featured interactive discussions.

JOURNAL OF CLINICAL DENSITOMETRY (2022)

Review Medicine, General & Internal

Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing

Yevgeniya Kushchayeva, Iryna Pestun, Sergiy Kushchayev, Nataliia Radzikhovska, E. Michael Lewiecki

Summary: Osteoporosis and osteoarthritis, both age-related disorders, may require surgical treatment. Poor bone quality can negatively impact surgical outcomes. This review summarizes the pathophysiology of osteoporotic bone healing, the effect of fractures on bone turnover markers, the diagnosis of low bone mineral density before surgery, and the effectiveness of anti-osteoporosis treatment.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Endocrinology & Metabolism

Cardiovascular Impact of Calcium and Vitamin D Supplements: A Narrative Review

Fatima Zarzour, Ahmad Didi, Mohammed Almohaya, David Kendler

Summary: Calcium and vitamin D play important roles in mineral homeostasis and skeletal health. The effectiveness and cardiovascular safety of their supplementation have been studied in various trials, yielding inconsistent results. Current guidelines recommend up to 1,200 mg of calcium intake from the diet without concern for cardiovascular risk. Recommendations for vitamin D supplementation vary widely, but well-conducted randomized trials suggest that modest supplementation is safe but does not provide cardiovascular benefits or harms.

ENDOCRINOLOGY AND METABOLISM (2023)

Article Endocrinology & Metabolism

Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study

E. Michael Lewiecki, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M. Nattrass, Neil Binkley, Miriam Annett, Leny Pearman, Bruce Mitlak

Summary: This study evaluated the safety and efficacy of the abaloparatide microstructured transdermal system (abaloparatide-sMTS) as an alternative to subcutaneous injection. The results showed that the abaloparatide-sMTS was not noninferior to the subcutaneous injection in terms of lumbar spine bone density at 12 months, but both treatments significantly increased lumbar spine and total hip bone density.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Review Endocrinology & Metabolism

Proceedings of the 2023 Santa Fe bone symposium: Progress and controversies in the management of patients with skeletal diseases

E. Michael Lewiecki, Teresita Bellido, John P. Bilezikian, Jacques P. Brown, Azeez Farooki, Christopher S. Kovacs, Brendan Lee, William D. Leslie, Michael R. McClung, Mark L. Prasarn, Deborah E. Sellmeyer

Summary: The 23rd annual Santa Fe Bone Symposium brought together attendees from various states and countries to discuss topics related to osteoporosis and other bone diseases. The event included plenary presentations, panel discussions, workshops, and oral presentations of research abstracts.

JOURNAL OF CLINICAL DENSITOMETRY (2023)

Review Endocrinology & Metabolism

Anabolic therapy for osteoporosis: update on efficacy and safety

Leonardo Bandeira, E. Michael Lewiecki

Summary: Anabolic agents increase bone density, improve bone strength, and reduce fracture risk. They work by increasing osteoblastic bone formation, distinguishing them from antiresorptive drugs. However, the bone forming effects of anabolic therapy are self-limited, necessitating the use of antiresorptive therapy to enhance the benefits achieved.

ARCHIVES OF ENDOCRINOLOGY METABOLISM (2022)

Article Endocrinology & Metabolism

Whole Body, Whole Life, Whole Family: Patients' Perspectives on X-Linked Hypophosphatemia

Amber A. Hamilton, Susan Faitos, Gin Jones, Athina Kinsley, Rupal Naik Gupta, E. Michael Lewiecki

Summary: X-linked hypophosphatemia (XLH), a genetic disorder, is often thought to only impact children, leading to insufficient care for adult patients. However, studies have shown that XLH has long-term adverse effects on patients' whole body, whole life, and whole family, necessitating comprehensive lifelong care.

JOURNAL OF THE ENDOCRINE SOCIETY (2022)

暂无数据